Cost-effectiveness analysis of pre-exposure prophylaxis for the prevention of HIV in men who have sex with men in South Korea: a mathematical modelling study by 구남수 et al.
1
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:14609  | https://doi.org/10.1038/s41598-020-71565-y
www.nature.com/scientificreports
Cost‑effectiveness analysis 
of pre‑exposure prophylaxis 
for the prevention of HIV in men 
who have sex with men in South 
Korea: a mathematical modelling 
study
Heun Choi1,9, Jiyeon Suh2,9, Woonji Lee1, Jun Hyoung Kim1, Jung Ho Kim1, Hye Seong1, 
Jin Young Ahn1, Su Jin Jeong1, Nam Su Ku1, Yoon Soo Park1, Joon Sup Yeom1, Changsoo Kim3, 
Hee‑Dae Kwon4, Davey M. Smith5,6, Jeehyun Lee2,7 & Jun Yong Choi1,8*
In February 2018, the Ministry of Food and Drug Safety in Korea approved tenofovir disoproxil 
fumarate and emtricitabine (TDF/FTC) co‑formulate for use in pre‑exposure prophylaxis (PrEP) for 
the prevention of human immunodeficiency virus (HIV) infection. This study aimed to estimate the 
cost‑effectiveness of PrEP in men who have sex with men (MSM), a major risk group emerging in 
Korea. A dynamic compartmental model was developed for HIV transmission and progression in 
MSM aged 15–64 years. With a combined model including economic analysis, we estimated averted 
HIV infections, changes in HIV prevalence, discounted costs, quality‑adjusted life‑years (QALYs), 
and incremental cost‑effectiveness ratios (ICERs). PrEP was evaluated in both the general MSM and 
high‑risk MSM populations and was assumed to reduce infection risk by 80%. Implementing PrEP in all 
MSM would avert 75.2% HIV infections and facilitate a gain of 37,372 QALYs at a cost of $274,822 per 
QALY gained over 20 years relative to the status quo. Initiating PrEP in high‑risk MSM with an average 
of eight partners per year (around 20% of MSM) would improve the cost‑effectiveness, averting 
78.0% HIV infections and add 29,242 QALYs at a cost of $51,597 per QALY gained, which is within 
the willingness‑to‑pay threshold for Korea of $56,000/QALY gained. This result was highly sensitive 
to annual PrEP costs, quality‑of‑life for people who are on PrEP, and initial HIV prevalence. Initiating 
PrEP in a larger proportion of MSM in Korea would prevent more HIV infections, but at an increasing 
cost per QALY gained. Focusing PrEP on higher risk MSM and any reduction in PrEP cost would 
improve cost‑effectiveness.
According to UNAIDS, the number of new HIV infections in the world was down 35% in 2018 from 2000; how-
ever, the number of new annual infections in Korea increased from 244 to 1,206 over the same period, mainly 
open
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among men who have sex with men (MSM). Pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate 
(TDF) and emtricitabine (FTC) may help reduce the HIV epidemic in Korea.
In the iPrEx study, 2,499 men and male-to-female transgenders who have sex with men were randomized to 
either a daily fixed-dose combination of TDF and FTC or a placebo. TDF/FTC group was associated with a 44% 
relative risk reduction in HIV acquisition, and the efficacy was estimated at > 90% among those with detectable 
blood drug  levels1,2. With proven efficacy in HIV prevention, PrEP has been found to be safe and efficacious in 
various clinical trials and approved by the United States Food and Drug Administration (FDA) for use as PrEP 
in  20123–5.
Although PrEP has been shown to be an effective preventive measure for HIV infection, its costs are consider-
able. A mathematical modeling study showed that use of PrEP for HIV prevention in the general population of 
MSM in the US could prevent a substantial number of HIV infections, and although PrEP use in high-risk MSM 
was considered most cost-effective, it was estimate to result in annual expenditures over $4  billion6. Further, a 
mathematical modeling study suggested that a combination of PrEP and early diagnosis of HIV infection could 
be a very effective way to reduce HIV incidence in South Korea among  MSM7. Although TDF/FTC has been 
approved for use in PrEP by the Korean Ministry of Food and Drug Safety, the use of PrEP is not yet covered by 
Korean national health insurance, and the high cost of PrEP, at $480 per month for TDF/FTC can be a significant 
barrier for PrEP implementation in South Korea. In this study, a mathematical model of the HIV epidemic among 
MSM in South Korea was constructed to evaluate the cost-effectiveness and preventive effects of PrEP in terms 
of the MSM population in South Korea and drug costs.
Methods
Study design and model structure. We constructed a dynamic compartmental model of HIV infections 
among MSM in South Korea to assess the cost-effectiveness of PrEP for HIV prevention within this population 
(Fig. 1). The model estimated HIV prevalence, incidence, quality-adjusted life-years (QALYs), and healthcare 
cost of PrEP strategies among MSM in South Korea over 20 years. Our base-case analysis estimates HIV infec-
tions averted and incremental cost-effectiveness ratios (ICERs) associated with implementing each PrEP strat-
egy. All costs are presented in 2017 US dollars, which were 3% discounted annually. We programmed the model 
using MATLAB R2019a (MathWorks, Natick, Massachusetts).
We divided the population by HIV infection status, awareness of HIV status, and PrEP use. Persons with 
HIV were defined by HIV disease stage and treatment status. Initial HIV prevalence and annual incidence were 
considered as 7.95% and 1.38%,  respectively8–11. We assumed a PrEP duration of 20 years, which is the same as 
the simulation time, and estimated the cost-effectiveness of PrEP in two groups: general MSM and high-risk 
MSM. The model was solved for each group in a different simulation by changing the values of following three 
parameters: total population sizes of 217,280 for general MSM and 43,456 for high-risk MSM; initial prevalences 
of 7.95% for general MSM and 15% for high-risk MSM; and numbers of partners per year of five for general 
MSM and eight for high-risk MSM.
We assumed that the high-risk MSM population comprised 20% of the general MSM population and that 
the initial HIV prevalence therein was nearly double that of general  MSM8–11. Individuals entered the model at 
an age of 15 years and were followed for 20 years or until the age of 64 years. Mortality comprised HIV-related 
and non-HIV-related deaths.
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We confirmed with the Institutional Review Board (IRB) of Severance Hospital that ethics approval was not 
needed before this study began since we did not utilize any personally identifiable information about human 
subjects.
Parameters and values. Table S1 shows the parameter values for each of the variables, descriptions, and 
references. The values were decided by the best available local epidemiological data, literature reviews, investiga-
tor’s derivations, and calculations based on mathematical formulas. Demographic parameter values ( ρ : entry 
rate, µ : maturation rate, δ : non-AIDS death rate) were based on Korea census data, and sexual behavior ( n : num-
ber of partners), screening ( ψ : fraction of test, ωid : average duration of identification), treatment ( φ : fraction of 
starting ART, φ̂  : rate of starting ART, γ : rate of discontinuing ART), health care costs, and medical costs related 
to the MSM and HIV patients were obtained from the Korea Centers for Disease Control & Prevention (KCDC) 
surveillance data and National Health Insurance Claims  data11–17. These local epidemiological data described 
authenticity as demonstrated by references cited in the text. Other parameters related to disease transmission ( π : 
transmission rate) and progression ( θ : progression rate, α : AIDS death rate), sexual behavior ( u : condom usage, 
κ : condom effectiveness), testing ( pid : reduction of sexual behavior), drug efficacy ( ǫpr : PrEP efficacy, ǫtx : ART 
efficacy), and QALYs for each status, were taken by referring to the studies presented in Table S1.
We modeled HIV transmission via homosexual contact based on number of male sexual partners and aver-
age condom  use8,9,18. The probability of HIV transmission between serodiscordant partners depended on the 
infected individual’s disease stage and ART use, as well as the PrEP status of the uninfected  person19–22. HIV 
disease progression was based on the average time in each of four disease stages: acute infection, asymptomatic 
HIV, symptomatic HIV, and AIDS. Progression rates were based on HIV natural history and ART  status6,19,23,24. 
We assumed that all persons with HIV were offered ART, given recent guidelines recommending ART initiation 
for all HIV-infected individuals regardless of CD4 cell  counts25. The benefits of ART and suppression of viral 
replication included improved quality of life and reduced disease transmission, progression, and  mortality25. We 
assumed a 99% reduction in sexual infectivity due to ART use for treatment of HIV  infection6,19,21,26–28. To be 
treated, persons with HIV must be identified as infected. We assumed that 40% of MSM are currently screened 
annually using antibody tests. Accordingly, we assumed a 20% reduction in risky behavior for both infected and 
uninfected persons after HIV  screening19,29–31.
PrEP strategies. We considered two strategies: PrEP for the general MSM population and PrEP for high-
risk MSM. We compared PrEP strategies to the status quo of no PrEP use. We assumed that MSM receiving 
PrEP would begin immediately and would remain on PrEP for the 20-year time horizon or until aging out of 
the model. We based our PrEP protocol on the Korean guidelines on PrEP  use32. MSM were initiated on PrEP 
after a negative HIV antibody test, adequate calculated creatinine clearance, and testing for sexually transmitted 
infections. The PrEP regimen included daily TDF/FTC and physician visits four times per year, or every three 
months, at which time HIV-negative status was confirmed with an antibody test and risk-reduction counseling 
and condoms were provided. Additionally, sexually transmitted infection testing was performed every 6 months, 
and renal function was tested annually. Persons who became HIV infected while on PrEP were provided with 
appropriate counseling and discontinued PrEP once infection was detected. We assumed TDF/FTC reduces 
the probability of acquiring HIV by 80%, based on the overall reduction in incidence seen in previous study 
 subjects1,33–35. PrEP was more effective in preventing HIV infection in iPrEx subgroups with higher adherence; 
therefore, we varied PrEP efficacy in sensitivity analysis. Although risk compensation is a concern with PrEP 
use, there is no evidence regarding the effect of PrEP on sexual  risk30. Hence, in our base case, we assumed no 
change in risky behavior from counseling.
Various studies have assessed willingness and likelihood to use PrEP in surveyed MSM populations with 
varying  conclusions36–39. The percentage of MSM who will ultimately use PrEP is unknown and will depend on 
numerous factors, such as public health campaigns and access to healthcare. We focused our results on 20%, 
50%, and 100% of uninfected MSM initiating PrEP to illustrate differences in effectiveness and cost-effectiveness 
as the percentage of MSM on PrEP increases.
Health outcomes and costs. We simulated the population over time and calculated discounted costs for 
each PrEP use scenario. The key parameters and values for cost and QALY are shown in Tables S2 and S3. We 
estimated quality of life for each health state and adjusted the utilities based on the average age of the modeled 
population. We assumed no reduction in quality of life from PrEP, as clinical trials have shown minimal side 
effects from TDF/FTC1,32–35. In sensitivity analysis, we evaluated the impact of decreased quality of life while 
on PrEP, as study participants on PrEP were more likely than those on placebo to experience minor side effects 
such as  nausea1,32–35. We included costs associated with medical care in each health state, PrEP, and HIV testing 
and diagnosis to calculate total health-related costs. Baseline medical costs, HIV-related healthcare costs (with 
costs of associated co-morbidities), and cost of ART were estimated from the published  literature15,17,40. Costs of 
antiretrovirals (ARVs) for PrEP were estimated as the average monthly wholesale price of TDF/FTC14,15,17. Costs 
of non-ARV components of the PrEP protocol and the HIV testing protocol were calculated according to the 
medical fee schedules of the Korea Health Insurance Review and Assessment Service, 2015. We also included 
discounted health-related costs and QALYs for the remaining lifetime of the population in the model at the end 
of the time horizon and for individuals who matured out of the modeled population.
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Results
Current situation. Our model projected that 17,130 and 14,485 new HIV infection will occur over 20 years 
for general MSM and high-risk MSM, respectively, if PrEP will not at all be implemented in MSM in South 
Korea (Table 1). This means that 84.6% of new HIV cases would arise from contact between high-risk individu-
als, despite high-risk MSM only accounting for 20% of all MSM in our model. The prevalence of HIV would 
remain mostly constant for 20 years in the general MSM population, but will increase to 30.5% in high-risk MSM 
(Table 1, Fig. 2).
Prevented HIV cases by PrEP implementation. We projected the number of averted cases with new 
HIV infection by implementing PrEP in MSM population with different coverage rates (20%, 50%, and 100% of 
MSM population). Our prediction suggested that the number of prevented HIV infections by PrEP would reach 
12,880 cases and 11,294 cases if PrEP were distributed to 100% of general MSM and high-risk MSM, respectively. 
Compared with no PrEP, there would be 75.2% and 78.0% reductions in new HIV cases among each group over 
20 years (Table 1). Initiation of PrEP targeting high-risk MSM gives comparable numbers of averted cases with 
that in general MSM at the same proportion of PrEP introduction. This implies that similar numbers of new HIV 
cases can be averted by targeting high-risk MSM, with fewer numbers of MSM taking PrEP.
Over time, the prevalence of HIV infection for the general MSM slowly decreased, and at the end of the time 
horizon, there was a reduction of up to only 4% points. On the other hand, in the high-risk MSM population, the 
prevalence and incidence were greatly reduced, and in the case of 100% PrEP, the prevalence decreased by about 
22%. However, to reduce the prevalence, all high-risk MSM need to receive PrEP (Table 1, Fig. 2).
Cost‑effectiveness analysis. Considering the averted number of new infections, at the current price 
of TDF/FTC ($5,800/year), PrEP for general MSM population is predicted to gain 37,372 QALYs at a cost of 
$274,822 per QALY gained over 20 years relative to status quo. Initiating PrEP in high-risk MSM would improve 
the cost-effectiveness, adding 29,242 QALYs at a cost of $51,597 per QALY gained, within the Korea willingness-
to-pay threshold of $56,000/QALY gained. In each scenario, implementing PrEP for 100% of the general and 
high-risk MSM population at current TDF/FTC costs would result in the PrEP cost exceeding the sum of the 
other costs (Fig. 3). Because PrEP targeting high-risk MSM reduces a similar number of new HIV cases with a 
fewer number of individuals initiating PrEP, compared with targeting the general MSM, there is a considerable 
reduction of additional costs due to PrEP relative to the reduction of QALY gains. Consequently, the ICERs 
under the willingness-to-pay threshold could be achieved for PrEP initiation in high-risk MSM (Table 1).
Sensitivity analysis. We measured the sensitivity of ICER at distributing PrEP for 100% of high-risk MSM. 
First, all model parameters were perturbed ± 1% to compare the relative impact on ICERs among the param-
eters. Then, the sensitivity of the six most influential parameters were displayed in tornado diagrams (Fig. 4A). 
The cost-effectiveness of PrEP was highly sensitive to quality-of-life on PrEP, the number of partners, condom 
usage, annual PrEP cost, initial HIV prevalence, and PrEP efficacy. The quality-of-life factor for PrEP and TDF/
FTC cost are significant because ICER directly depends on changes in QALYs and cost. Cost-effectiveness is 
considerably sensitive to the number of partners and condom usage. These are involved in the transmission rate 
of HIV, which plays a key role in infection dynamics. The initial prevalence of HIV determines the initial values 
of each compartment, and the results of the compartmental model are often sensitive to those values. Efficacy of 
PrEP took the sixth place as it indicates the degree of prevention achieved by the main control measure in the 
scenario.
While the analysis of relative sensitivity varying the parameters at the same level is standard theoretically, it 
may not be reasonable in practice because the feasible range of each parameter can differ greatly. In this context, 
we evaluated sensitivity by varying the six most influential parameters within a feasible range (Fig. 4B). If we 
assume lower PrEP efficacy ordiscount quality of life factor due to PrEP relative to current values, the ICERs will 
Table 1.  Benefits and costs of PrEP strategies over 20 years in general men who have sex with men (MSM) 
and high-risk MSM.




HIV prevalence at 
20 years (%)
Incremental Costs 
(millions $) Incremental QALYs
ICER relative to No 
PrEP ($/QALY)
PrEP on general MSM
100% PrEP 4,250 12,880 (75.2%) 2.81 10,271 37,372 274,822
50% PrEP 9,612 7,518 (43.9%) 4.42 5,090 21,125 240,939
20% PrEP 13,812 3,318 (19.4%) 5.75 2,023 9,123 221,774
Status quo
(No PrEP) 17,130 6.84
PrEP on high-risk MSM
100% PrEP 3,191 11,294 (78.0%) 8.81 1,509 29,242 51,597
50% PrEP 7,672 6,813 (47.0%) 17.0 701 17,450 40,200
20% PrEP 11,468 3,017 (20.8%) 24.4 266 7,739 34,346
Status quo (No PrEP) 14,485 30.5
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Figure 2.  HIV prevalence and incidence over 20 years in general MSM (A,B) and high-risk MSM (C,D).
Figure 3.  Total costs, consisting of PrEP costs and other costs, for each PrEP use scenario of targeting 0%, 20%, 
50%, and 100% of general MSM (A) and high-risk MSM populations (B).
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soar above the willingness-to-pay threshold. Assuming more partners or less condom usage would make PrEP 
initiation more effective. Lowering the price of TDF/FTC would be a sure way to get ICERs under the threshold, 
and cost savings with a negative ICER value can be achieved if the price is reduced 10% though it may be unre-
alizable. PrEP is less cost-effective if the initial prevalence in high-risk MSM is less than 15%.
Parameters of interest were selected among the six most sensitive parameters to perform two-way sensitivity 
analysis. The region of PrEP efficacy and TDF/FTC cost satisfying the willingness-to-pay threshold of $56,000/
QALY gained is shown in heat maps (Fig. 5). With current PrEP efficacy (80%) and cost (100%), we can barely 
achieve cost-effectiveness by targeting PrEP to 100% of the high-risk MSM population. Reductions in the cost 
of TDF/FTC or improvements in PrEP efficacy would improve the cost-effectiveness of targeting PrEP to 100% 
of high-risk MSM. To achieve cost-effectiveness of 100% PrEP in general MSM, however, a 90% reduction in 
TDF/FTC cost is required, assuming PrEP efficacy is better than 40%. Two-way sensitivity was also analyzed in 
regards to region of initial prevalence of HIV infection and TDF/FTC cost to assess their combined impact on 
ICERs (Fig. 6). For the general MSM population, assuming a higher initial prevalence would not support the 
cost-effectiveness of PrEP unless the cost of TDF/FTC decreases to 10–20% of the current price. Meanwhile, 
100% PrEP initiation in high-risk MSM would be cost-effective when the initial prevalence is higher than now. 
Figure 4.  Tornado diagrams of ICERs with respect to the six most sensitive parameters at distributing PrEP for 
100% of high-risk MSM. (A) Relative sensitivity between the parameters with perturbation of parameters by ± 
1%. (B) Sensitivity by varying parameters within a feasible range.
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Even if it is lower than what we expect, ICERs lower than the willingness-to-pay threshold can be achieved by 
reducing the price of TDF/FTC up to 50%.
Discussion
According to a report from the KCDC, the cumulative number of confirmed HIV infections was 17,500 as of 
December 2018, and the number of newly-infected cases per year was 1,206 in  201812. Although the prevalence 
of confirmed HIV infections is still low in Korea (< 0.05%), the actual number of persons with HIV may be larger 
than reported by the Ministry, especially since the recent epidemiology of HIV infections in Korea is character-
ized by an increasing number of newly diagnosed HIV cases and proportion of late-presentation  diagnoses8,41–43. 
Based on self-reports of sexual practices in 2015, MSM and heterosexual contact accounted for 44% and 56% of 
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sexually transmitted cases, respectively. Given to the stigma attached to homosexuality within Korean society, 
the rate of MSM might be underestimated in the official report.
Despite efforts to overcome HIV, the number of newly diagnosed persons with HIV has continuously  risen12. 
Multiple prevention measures have the possibility of impacting HIV incidence in South Korea, including early 
diagnosis, early treatment, and PrEP. A previous study investigated how each of these interventions could impact 
the local HIV epidemic, especially among MSM, who have become a major risk group in South Korea, using a 
mathematical  model7. In a previous study, multiple prevention measures for HIV incidence in South Korea were 
considered, including early diagnosis, early treatment, and PrEP. The model simulation suggested that PrEP and 
early diagnosis could be effective at reducing HIV incidence in South Korea among MSM. However, the study did 
not consider cost-effectiveness of interventions, which would be important to help guide public health  decisions44.
In our study, which is the first to estimate cost-effectiveness of PrEP in South Korea, we demonstrated that 
implementing PrEP in high-risk MSM (presumably 20% of MSM) would improve the cost-effectiveness, within 
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the South Korea willingness-to-pay threshold of $56,000/QALY gained, and the cost-effectiveness of PrEP was 
highly sensitive to annual PrEP cost, quality-of-life on PrEP, and initial HIV prevalence. However, distributing 
PrEP for all MSM seems not to be cost-effective in South Korea. Total costs over 20 years for PrEP in all MSM 
was expected to be much higher than total costs for PrEP in high-risk MSM. Since the cost-effectiveness estimates 
were derived from parameter values of current epidemiology of South Korea, the estimates depend on epidemic 
changes, and it is unclear from the modeling whether increasing early diagnosis among MSM in South Korea 
would change these estimates.
Our findings in Korea that targeting PrEP to for high-risk MSM and any reduction in PrEP cost would 
improve cost-effectiveness in Korea are consistent with literature in other countries, including the United States 
and  Australia30,45–48. Several of previous studies using mathematical models have shown the necessity of targeting 
PrEP to MSM at high risk of HIV infection for PrEP to be cost-effective30,45–47. Another study, which focused on 
a targeted PrEP strategy, found diminishing cost-effectiveness ratios with larger proportions of high-risk MSM 
on  PrEP48. Considering the willingness-to-pay threshold in South Korea, it was barely cost-effective by applying 
PrEP only to high-risk MSM population.
The cost-effectiveness of PrEP was highly sensitive to annual PrEP cost, and a price reduction could decrease 
the cost-effectiveness ratio. In South Korea, generic ARVs are not available, and the PrEP cost for this study was 
calculated with the price of original TDF/FTC. Given that the patent for TDF/FTC will expire, price reductions 
can be expected in future. In addition, we do not know the future prices of ARVs for treatment of HIV infection. 
The prices of future ARVs might affect our results.
This study has several limitations. First, our model was not stratified by the level of HIV infection risk. To 
take this into the model, data regarding contact patterns between heterogeneous risk groups are required for 
the calibration of the model. No reliable sources about sexual behaviors between the risk groups are available 
in South Korea, however, future studies should consider surveys to quantify contact patterns. Second, we did 
not include an on-demand PrEP strategy in our model. A previous study demonstrated the effect of on-demand 
PrEP for high-risk  MSM49. Given the higher cost of daily PrEP, the cost-effectiveness ratio of on-demand PrEP 
might increase. Third, our results might be limited, and our estimates might also be biased because we included 
parameter estimates from Western countries, as with most mathematical models. Data from other countries could 
influence the conclusions of our study. Fourth, our derivations of some parameters were not validated, although 
they were based on the best available epidemiologic data. For example, we estimated the initial prevalence of 
MSM by analyzing HIV incidence, sex ratio, and results in the literature. Also, no change in risk behavior after 
PrEP was assumed. It has, however, been reported that its impact on PrEP effectiveness is not significant by a 
previous  study7. Fifth, improvements in HIV care cascade towards UNAIDS 90–90–90 goal and new therapeutics 
including HIV vaccine have not been considered over the next 20 years, because it is not feasible to quantify the 
impact of those on HIV incidence. Consequently, the observed effectiveness of PrEP may involve overestimation 
of the prevalence of HIV.
Conclusion
Initiating PrEP in a larger proportion of MSM in Korea would prevent more HIV infections, although at an 
increasing cost per QALY gained. PrEP only in high-risk MSM and reductions in the drug costs for PrEP would 
improve cost-effectiveness.
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